Deficient p27 phosphorylation at serine 10 increases macrophage foam cell formation and aggravates atherosclerosis through a proliferation-independent mechanism

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 11, 2011, Pages 2455-2463

  Fuster, José J ^a   González Navarro, Herminia ^c,g   Vinué, Angela ^c   Molina Sànchez, Pedro ^a   Andrés Manzano, Maria J ^a   Nakayama, Keiichi I ^d   Nakayama, Keiko ^e   Díez Juan, Antonio ^b,h   Bernad, Antonio ^b   Rodríguez, Cristina ^f   Martínez González, José ^f   Andrés, Vicente ^a  

^a Laboratory of Molecular and Genetic Cardiovascular Pathophysiology   (Spain)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c INSTITUTO DE BIOMEDICINA DE VALENCIA   (Spain)

^d KYUSHU UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^g HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^h CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

atherosclerosis; genetically altered mice; molecular biology; p27; Rho

Indexed keywords

APOLIPOPROTEIN E; EZRIN; MOESIN; PROTEIN P27; RADIXIN; RHO ASSOCIATED COILED COIL CONTAINING PROTEIN KINASE; RHO KINASE; SERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; BONE MARROW; CONTROLLED STUDY; CORONARY ARTERY; DISEASE COURSE; ENZYME ACTIVATION; FEMALE; FOAM CELL; HUMAN; IMMUNOBLOTTING; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING;

ANIMALS; APOLIPOPROTEINS E; ARTERIES; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; FOAM CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORYLATION; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES; SERINE; SIGNAL TRANSDUCTION;

EID: 80054934052     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.235580     Document Type: Article

References (46)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
2. Lusis AJ. Atherosclerosis Nature. 2000;407:233-241.
3. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104: 503-516. (Pubitemid 32201946)
4. Fuster JJ, Fernandez P, Gonzalez-Navarro H, Silvestre C, Abu Nabah YN, Andres V. Control of cell proliferation in atherosclerosis: insights from animal models and human studies. Cardiovasc Res. 2010;86: 254-264.
5. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002;8:1249-1256. (Pubitemid 35373556)
6. Vidal A, Koff A. CellAcycle inhibitors: three families united by a common cause. Gene. 2000;247:1-15. (Pubitemid 30201556)
7. Borriello A, Cucciolla V, Oliva A, Zappia V, Della Ragione F. p27Kip1 metabolism: a fascinating labyrinth. Cell Cycle. 2007;6:1053-1061.
8. Vervoorts J, Lüscher B. Post-translational regulation of the tumor suppressor p27 KIP1. Cell Mol Life Sci. 2008;65:3255-3264.
9. Ishida N, Kitagawa M, Hatakeyama S, Nakayama K-i. Phosphorylation at serine 10, a major phosphorylation site of p27Kip1, increases its protein stability. J Biol Chem. 2000;275:25146-25154.
10. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M, Meloche S. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J. 2001;20:6672-6682. (Pubitemid 33134197)
11. Kawauchi T, Chihama K, Nabeshima Y-i, Hoshino M. Cdk5 phosphorylates and stabilizes p27kip1 contributing to actin organization and cortical neuronal migration. Nat Cell Biol. 2006;8:17-26. (Pubitemid 43064793)
12. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ, Nabel EG. A growth factor-dependent nuclear kinase phosphorylates p27Kip1 and regulates cell cycle progression. EMBO J. 2002;21: 3390-3401. (Pubitemid 34760571)
13. Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E. The cyclindependent kinase inhibitor p27Kip1 is stabilized in G0 by Mirk/dyrk1B kinase. J Biol Chem. 2004;279:22498-22504. (Pubitemid 38679449)
14. Kotake Y, Nakayama K, Ishida N, Nakayama KI. Role of serine 10 phosphorylation in p27 stabilization revealed by analysis of p27 knock-in mice harboring a serine 10 mutation. J Biol Chem. 2005;280:1095-1102.
15. Besson A, Gurian-West M, Chen X, Kelly-Spratt KS, Kemp CJ, Roberts JM. A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev. 2006;20:47-64. (Pubitemid 43042667)
16. Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K, Nakayama KI. Phosphorylation of p27 Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem. 2002;277:14355-14358. (Pubitemid 34952496)
17. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer. 2008;8:253-267. (Pubitemid 351430863)
18. Chen D, Krasinski K, Sylvester A, Chen J, Nisen PD, Andrés V. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J Clin Invest. 1997;99: 2334-2341. (Pubitemid 27227709)
19. Tanner FC, Boehm M, Akyurek LM, San H, Yang Z-Y, Tashiro J, Nabel GJ, Nabel EG. Differential effects of the cyclin-dependent kinase inhibitors p27Kip1, p21Cip1, and p16Ink4 on vascular smooth muscle cell proliferation. Circulation. 2000;101:2022-2025. (Pubitemid 30233162)
20. Diez-Juan A, Andres V. The growth suppressor p27Kip1 protects against diet-induced atherosclerosis. FASEB J. 2001;15:1989-1995. (Pubitemid 32848803)
21. Diez-Juan A, Perez P, Aracil M, Sancho D, Bernad A, Sanchez-Madrid F, Andres V. Selective inactivation of p27Kip1 in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis. Blood. 2004;103:158-161. (Pubitemid 38029933)
22. Akyürek LM, Boehm M, Olive M, Zhou A-X, San H, Nabel EG. Deficiency of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1 accelerates atherogenesis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 2010;396:359-363.
23. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008;14:159-169. (Pubitemid 351189186)
24. Sanz-González SM, Melero-Fernández-de-Mera R, Malek NP, Andrés V. Atheroma development in apolipoprotein E-null mice is not regulated by phosphorylation of p27Kip1 on threonine 187. J Cell Biochem. 2006;97: 735-743.
25. Sanz-González SM, Barquin L, GarciaAcao I, Roque M, Gonzalez JM, Fuster JJ, Castells MT, Flores JM, Serrano M, Andres V. Increased p53 gene dosage reduces neointimal thickening induced by mechanical injury but has no effect on native atherosclerosis. Cardiovasc Res. 2007;75: 803-812. (Pubitemid 47238733)
26. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med. 2006;203:1273.
27. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev. 2004;18:862-876. (Pubitemid 38529656)
28. Rolfe BE, Worth NF, World CJ, Campbell JH, Campbell GR. Rho and vascular disease. Atherosclerosis. 2005;183:1-16. (Pubitemid 41416816)
29. Zhou Q, Liao JK. Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des. 2009;15:3108-3115.
30. Rekhter M, Chandrasekhar K, Gifford-Moore D, Huang X, Rutherford P, Hanson J, Kauffman R. Immunohistochemical analysis of target proteins of Rho-kinase in a mouse model of accelerated atherosclerosis. Exp Clin Card. 2007;12:169-174.
31. Wang H-W, Liu P-Y, Oyama N, Rikitake Y, Kitamoto S, Gitlin J, Liao JK, Boisvert WA. Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLRF/2mice. FASEB J. 2008;22: 3561-3570.
32. Ihling C, Technau K, Gross V, Schulte-Mönting J, Zeiher AM, Schaefer HE. Concordant upregulation of type II-TGFAc-receptor, the cyclin-dependent kinases inhibitor P27Kip1 and cyclin E in human atherosclerotic tissue: implications for lesion cellularity. Atherosclerosis. 1999;144:7-14. (Pubitemid 29259960)
33. Tanner FC, Yang Z-Y, Duckers E, Gordon D, Nabel GJ, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ Res. 1998;82:396-403. (Pubitemid 28101197)
34. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai L-H, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27Kip1-deficient mice. Cell. 1996;85:733-744.
35. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell. 1996;85:721-732.
36. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K-i. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996;85:707-720.
37. McAllister SS, Becker-Hapak M, Pintucci G, Pagano M, Dowdy SF. Novel p27kip1 C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol. 2003;23:216-228. (Pubitemid 36008515)
38. Moeller SJ, Head ED, Sheaff RJ. p27Kip1 inhibition of GRB2-SOS formation can regulate Ras activation. Mol Cell Biol. 2003;23: 3735-3752. (Pubitemid 36597455)
39. Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol. 2008;9: 690-701.
40. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98:322-334.
41. Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu P-Y, Wang H, Ahl D, Sawada N, Okamoto R, Hiroi Y, Shimizu K, Luscinskas FW, Sun J, Liao JK. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest. 2008;118:1632-1644. (Pubitemid 351632368)
42. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun T-H, Inoue M, Masatsugu K, Saito T, Fukunaga Y, Sakaguchi S, Arai H, Ohno N, Komeda M, Nakao K. Inhibition of Rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation. 2000;101:2030-2033. (Pubitemid 30233164)
43. Mallat Z, Gojova A, Sauzeau V, Brun V, Silvestre J-S, Esposito B, Merval R, Groux H, Loirand G, Tedgui A. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res. 2003;93:884-888. (Pubitemid 37363063)
44. Wu DJ, Xu JZ, Wu YJ, JeanAcharles L, Xiao B, Gao PJ, Zhu DL. Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice. Atherosclerosis. 2009; 207:68-73.
45. Yoneda A, Multhaupt HAB, Couchman JR. The Rho kinases I and II regulate different aspects of myosin II activity. J Cell Biol. 2005;170: 443-453. (Pubitemid 41126943)
46. Chimini G, Chavrier P. Function of Rho family proteins in actin dynamics during phagocytosis and engulfment. Nat Cell Biol. 2000;2:E191-E196.